CROI ART/HIV Drug Studies

Conference Reports for NATAP

Conference on Retroviruses
and Opportunistic Infections
Boston USA
March 8-11, 2020


CROI ART/HIV Drug Studies

	STRUCTURAL ANALYSES OF A BOUND ANTI-CD4 ADNECTIN INHIBITOR OF HIV-1 [Combinectin GSK3732394] - (03/11/20) Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2M study Every-2-Month Maintenance CAB + RPV Noninferior to Monthly Dosing for 48 Weeks - (03/09/20) Potential Drugs for Multi-drug Resistant HIV NOVEL ANTIRETROVIRAL AGENTS: TRANSFORMING THE CARE OF PEOPLE WITH HIV - (03/11/20) Preexisting Resistance and B/F/TAF Switch Efficacy in African Americans (03/13/20) RANDOMIZED SWITCH TO B/F/TAF IN AFRICAN AMERICAN ADULTS WITH HIV - (03/12/20) 144-Week Efficacy and Safety of B/F/TAF in Treatment-Naive Adults Age ≥50 Years - (03/12/20) DTG + 3TC VS DTG + TDF/FTC (GEMINI-1 & -2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96 - (03/11/20) LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV TREATMENT: FLAIR WEEK 96 RESULTS - (03/11/20) Use of D/C/F/TAF With Neurologic/Psychiatric Comorbidities: AMBER Subgroup Analysis (03/16/20) Risks of metabolic syndrome, diabetes, and cardiovascular disease in ADVANCE trial. Predicted Rise in Diabetes Risk With TAF/FTC+DTG Versus TDF/FTC+DTG- (03/12/20) FOSTEMSAVIR EXPOSURE-RESPONSE RELATIONSHIPS IN TREATMENT EXPERIENCED HIV PATIENTS (03/16/20) CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION (03/16/20) DOSE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS LONG-ACTING HIV CAPSID INHIBITOR GS-6207 (03/16/20) ABSENCE OF GS-6207 PHENOTYPIC RESISTANCE IN HIV Gag CLEAVAGE SITE AND OTHER MUTANTS (03/16/20) PK, Food Effect, and Safety of Oral GS-6207, a Novel HIV-1 Capsid Inhibitor (03/16/20) Islatravir Metabolic Outcomes in a Phase 2b Trial of Treatment-Naïve Adults with HIV-1 - (03/09/20) 75 CROI NATAP Reports Conference on Retroviruses and Opportunistic Infections Boston USA March 8-11, 2020